

10th MDS Colloquium featuring the 7th Annual EMSCO Meeting

9th November 2019

| Session 1: EMSCO trial update | | Chair: TBD |
|-------------------------------|--|--|
| 08:30 | Update on ongoing trials | Silke Gloaguen, Dresden Fatiha Chermat, Paris |
| 08:50 | EMSCO trials in the pipeline | Uwe Platzbecker, Leipzig Lionel Adès, Paris |
| 09:10 | Snapshot of current global clinical research in MDS | Pierre Fenaux, Paris |
| 09:30 | Regulatory aspects of clinical trials → EU 536 | Oana Brosteanu, Leipzig |

Coffee break

| Session 2: Pathophysiology & prognosis | | Chair: TBD |
|--|--|------------------------------|
| 10:10 | Stem cell hierarchy in MDS – different than expected? | Amit K. Verma, New York |
| 10:30 | Niche and MDS: druggable targets? | Daniel Nowak, Mannheim |
| 10:50 | Iron and MDS: fake or fiction? | Emanuele Angelucci, Cagliari |
| 11:10 | Molecular prognostic markers in MDS and AML | Felicitas Thol, Hannover |

Coffee break

| Session 3: Therapy of MDS and AML | | Chair: TBD |
|-----------------------------------|---|---------------------------|
| 11:50 | Standards and perspectives of treatment in lower-risk MDS – ESA first, EMA second? | Uwe Platzbecker, Leipzig |
| 12:10 | HMA in MDS and AML. Isn't there any biomarker of outcome and response? | Valeria Santini, Florence |
| 12:30 | Are there any novel concepts of allogeneic transplant in myeloid disorders? | Guillermo Sanz, Valencia |

Lunch

| Session 4: New targets in MDS and AML | | Chair: TBD |
|---------------------------------------|---|-------------------------|
| 13:50 | How to improve outcome of high-risk MDS and AML in the elderly? | Lionel Adès, Paris |
| 14:10 | IDH1 and 2 revisited – a druggable target with curative potential? | Paresh Vyas, Oxford |
| 14:30 | Moving from bench to bedside in myeloid malignancies: the future of AML/MDS? | Raphael Itzykson, Paris |

Coffee break

| Session 5: Plenary I | | Chair: TBD |
|----------------------|--|--------------------------|
| 15:10 | Inflammation in bone marrow failure, fact or artefact? | Shahram Kordasti, London |
| 15:35 | Inherited bone marrow failure syndromes – only a matter of paediatrics? | Marie Sebert, Paris |
| 16:00 | Dyserythropoiesis in MDS – causes and consequences | Michaela Fontenay, Paris |

Coffee break

| Session 6: Plenary II | | Chair: TBD |
|-----------------------|--|------------------------|
| 16:45 | Presence and future of cellular therapy in hematology | Ulrike Köhl, Leipzig |
| 17:15 | MDS/MPN, beyond genomic alterations | Eric Solary, Villejuif |

Adjourn